Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
178.6 EUR | +0.90% |
|
-0.11% | -32.20% |
11:35am | SARTORIUS VORZUEGE : Barclays reiterates its Neutral rating | ZD |
06-20 | SARTORIUS VORZUEGE : UBS remains Neutral | ZD |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- One of the major weak points of the company is its financial situation.
- With an expected P/E ratio at 61.33 and 42.31 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.20% | 14.88B | - | ||
-54.19% | 2.26B | C+ | ||
+19.59% | 1.89B | - | ||
-8.65% | 1.52B | - | ||
+18.03% | 1.19B | B+ | ||
-24.23% | 871M | - | ||
+1.62% | 781M | - | ||
-34.22% | 750M | - | C- | |
-29.46% | 591M | B+ | ||
+17.92% | 560M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SRT3 Stock
- SRT Stock
- Ratings Sartorius AG